US President Joe Biden's administration on Wednesday announced support for a global waiver on patent protections for COVID-19 vaccines, offering hope to poor nations that have struggled to access the life-saving doses.
May 5, 2021
0
5
The world has a COVID-19 vaccine access problem: Almost half of all doses administered so far have been in Europe and North America, while many poorer countries have vaccinated less than than 1% of their populations.
Apr 15, 2021
0
2
In an industrial neighborhood on the outskirts of Bangladesh's largest city lies a factory with gleaming new equipment imported from Germany, its immaculate hallways lined with hermetically sealed rooms. It is operating at ...
Mar 1, 2021
0
9
A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.S. Food and Drug Administration.
Aug 19, 2020
0
2
With research laboratories around the world racing to develop a coronavirus vaccine, a unique challenge has emerged: how to balance intellectual property rights with serving the public good.
May 29, 2020
0
4
The high price of insulin, which has reached as much as US$450 per month, has raised outrage across the country. Sen. Bernie Sanders (I-Vt.) has called it a national embarrassment, wondering why U.S. residents should have ...
Jan 28, 2020
0
2
A US-led Pacific free trade pact faces further delays as a row between Big Pharma and activists supporting access to generic drugs erupts ahead of an October deadline, officials say.
Mar 10, 2013
1
0
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive ...
Mar 5, 2013
3
0
German pharmaceuticals giant Bayer, maker of Aspirin, vowed Monday to fight a ruling by the patent authorities in India allowing a local company to produce and sell a generic copy of its anti-cancer drug Nexavar.
Mar 4, 2013
0
0
Pharmaceutical giant Bayer AG on Wednesday said it was "disappointed" with an Indian ruling that allows a local firm to produce a cheaper copy of its patented drug Nexavar for liver and lung cancer.
Sep 26, 2012
0
0
